terfenadine has been researched along with Breast Cancer in 3 studies
Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Paclitaxel (PTX) is one of the most important breast cancer treatment drugs." | 7.76 | [Administration of premedication with fexofenadine for paclitaxel-induced hypersensitive reactions in breast cancer patients complicated with closed-angle glaucoma]. ( Eguchi, H; Kogure, Y; Komatsubara, K; Matsuhisa, T; Miyoshi, K, 2010) |
| " Oral area under the plasma concentration-time curve (AUC) and bioavailability of well known BCRP (sulfasalazine and rosuvastatin), P-glycoprotein (fexofenadine, aliskiren, and talinolol), and CYP3A (midazolam) substrates were investigated in the presence and absence of inhibitors." | 5.48 | Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys. ( Abe, K; Ando, O; Imaoka, T; Karibe, T, 2018) |
| "Paclitaxel (PTX) is one of the most important breast cancer treatment drugs." | 3.76 | [Administration of premedication with fexofenadine for paclitaxel-induced hypersensitive reactions in breast cancer patients complicated with closed-angle glaucoma]. ( Eguchi, H; Kogure, Y; Komatsubara, K; Matsuhisa, T; Miyoshi, K, 2010) |
| " Oral area under the plasma concentration-time curve (AUC) and bioavailability of well known BCRP (sulfasalazine and rosuvastatin), P-glycoprotein (fexofenadine, aliskiren, and talinolol), and CYP3A (midazolam) substrates were investigated in the presence and absence of inhibitors." | 1.48 | Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys. ( Abe, K; Ando, O; Imaoka, T; Karibe, T, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Karibe, T | 1 |
| Imaoka, T | 1 |
| Abe, K | 1 |
| Ando, O | 1 |
| Fernández-Nogueira, P | 1 |
| Noguera-Castells, A | 1 |
| Fuster, G | 1 |
| Recalde-Percaz, L | 1 |
| Moragas, N | 1 |
| López-Plana, A | 1 |
| Enreig, E | 1 |
| Jauregui, P | 1 |
| Carbó, N | 1 |
| Almendro, V | 1 |
| Gascón, P | 1 |
| Bragado, P | 1 |
| Mancino, M | 1 |
| Komatsubara, K | 1 |
| Miyoshi, K | 1 |
| Kogure, Y | 1 |
| Matsuhisa, T | 1 |
| Eguchi, H | 1 |
3 other studies available for terfenadine and Breast Cancer
| Article | Year |
|---|---|
Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; ATP Binding Cassette Transporter, Subfamily B, Mem | 2018 |
Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neo | 2018 |
[Administration of premedication with fexofenadine for paclitaxel-induced hypersensitive reactions in breast cancer patients complicated with closed-angle glaucoma].
Topics: Anti-Allergic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Hypersensitivity; Fe | 2010 |